1. Scrip

EASL: Sagimet Pill Is Overlooked But Could Make A Splash In MASH

 
• By Andrew McConaghie

While injectables have had all the limelight, some analysts see a bright future for Sagimet’s oral denifanstat, potentially as a backbone therapy in combination with other treatments for MASH.

Allianz MiCo Milan
The EASL 2024 congress was held at the Allianz MiCo in Milan, Italy. • Source: Shutterstock

Weekly injectable drugs are seen as future market leaders in metabolic dysfunction-associated steatohepatitis (MASH), but there may be room for oral drugs to treat the liver disease, and analysts have concluded that strong Phase II data have boosted the chances of Sagimet Biosciences’s denifanstat.

The update on the daily pill product was presented at the European Association for the Study of the Liver Congress...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.